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Summary In 82 patients with stage III malignant melanoma, the primary tumours were investigated by DNA
flow cytometry. The tumours were classified as DNA diploid (n = 36), tetraploid (n = l1) and aneuploid
(n = 35). By univariate analysis a significant correlation with post-recurrence survival was found for time to
first metastasis, DNA-ploidy and S-phase fraction.
By multivariate analysis, significant prognostic variables were found to be the time to first metastasis
(P = 0.006), and ploidy (P = 0.011). Patients with diploid melanomas and a long recurrence-free interval had a
median post-recurrence survival time of 45 months compared to 18 months in patients with DNA aneuploid
tumours and an early recurrence.
The S-phase could be estimated in 47 primary melanomas and was found to be a significant prognostic
variable (P = 0.017). The median survival was 45 months for patients with melanomas with a S-phase fraction
below 5%, and 19 months for melanomas with S-phase above 10%. The prognostic value of the S-phase
remained significant even after adjustment for recurrence-free interval and DNA ploidy.
The prognostic importance of DNA ploidy and S-phase
estimated by flow cytometry has been elucidated for a
number of different neoplasms (Lenner et al., 1987;
Rosenberg et al., 1989; Stal et al., 1989). To some extent this
technique has also been applied to malignant melanomas.
Thus Kheir et al. (1988) in a multivariate analysis of estab-
lished predictors found that, after the thickness of the
primary melanoma lesion, aneuploidy of the tumour cells was
the most significant independent prognostic variable. It was
strongly correlated to established predictors of unfavorable
prognosis. Further Buchner et al. (1985) found that DNA
aneuploidy was correlated to the thickness of the primary
melanoma. Another study did not find any relation between
ploidy and age, sex, site of origin, histological type, grade of
invasion or even melanoma thickness (Lindholm et al., 1990).
In melanoma metastases Hansson et al. (1982) found the
S-phase to be correlated to prognosis, but ploidy was
not.
Some malignant melanomas give early metastases, while
others have a long latency period before recurrence after
primary surgery. Metastatic types include in transit metas-
tases, regional lymph node metastases (stage III) and distant
metastases (stage IV).
The aim of the present study was to investigate if DNA
ploidy and fraction of primary melanoma cells in S-phase
provide prognostic information for stage III melanoma
patients.
Material and methods
Patients
We analysed 82 patients with stage III melanoma disease.
Fifty-seven patients were treated at the Department of Plastic
Surgery, University Hospital, Linkoping (group A) and 25
patients were treated at the Department of Plastic Surgery,
Sahlgrens Hospital, University of Gothenburg (group B).
The surgical treatment by wide excision of the primary
melanoma was identical in the two groups, and the patients
were considered disease-free. After the disease-free interval
(time to first metastasis), patients found with cutaneous
metastases were treated with wide excisions and in patients
with lymph node metastases therapeutic node dissections
were performed. Patients in group A received adjuvant
chemotherapy with 5-(3,3-dimethyl-l-triazeno)imidazole-4-
carboxamide (DTIC) when they developed stage III disease.
In group B no adjuvant chemotherapy was given. Group B
comes from a previously described cohort of stage I patients
(Eldh et al., 1978).
The malignant melanoma in group A were diagnosed
between 1969 and 1984 and in group B between 1966 and
1974. The total follow up period was 7 to 25 years. The mean
potential follow up time after recurrence was 12 years and 8
months. There were no significant differences in sex, age,
growth pattern, level of invasion, tumour thickness, presence
or absence of ulceration and site of origin of the melanoma
between the two groups. In group B the time to first metas-
tasis tended to be longer (mean 31.2 months) than in group
A (mean 17.5 months), but the difference was not statistically
significant (P = 0.054).
In group A 12 patients were alive February 1991. Two
patients died of squamous cell carcinoma of the lung and
duodenal cancer respectively, 10 and 3.5 years after surgery
for the primary melanoma. Another patient had a fatal heart
infarction 10.5 years after the melanoma diagnosis. These
three patients were in complete melanoma remission at death.
The other 42 patients in group A had a mean survival of 24.5
months (range 4-68 months) after recurrence, and died with
disseminated malignant melanoma. Two patients in group B
were still alive February 1991, and in this group four patients
died from intercurrent diseases. The 19 patients in group B,
who died by dissemination of malignant melanoma had a
mean survival time after first metastasis of 20.7 months
(range 2-61 months).
Cytometry
An area with high density of tumour cells was identified on
the hematoxylin-eosin stained section and the corresponding
area on a 50 gLm section from the formalin fixed paraffin-
embedded material was identified and deparaffinised in
xylene. Hydration was performed in a sequence of ethanol
solutions in water (99.5%, 95%, 70% and 40%), and finally
the specimens were washed twice with 5-ml aliquots of dis-
tilled water. Centrifugations between each change of solution
were at 500 g for 10 min. Enzyme treatment was performed
with 0.25% trypsin (T0134, Sigma), dissolved in 3 mM citrate
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Table I Survival in relation to different characteristics
(univariate analysis)
of stage III melanomas
95%
Variable Median survival confidence Log-rank
category n (mo) interval test
57
25
31
51
26
28
28
4
42
29
7
2
25
34
21
21
42
19
33
29
20
13
37
12
20
44
22
16
36
11
35
Hospital
Linkoping
Gothenberg
Sex
Women
Men
Age
<50 years
50-64 years
>65 years
Growth pattern
Acral mal.melanoma
Nodular mal.melanoma
Superfic. mal.melanoma
Lentigo mal.melanoma
Level of invasion
Clark II
Clark III
Clark IV
Clark V
Thickness
<2.0 mm
2.1 5.0 mm
>5.0 mm
Ulceration
No ulceration
<6 mm ulceration
>6 mm ulceration
Site of origin
Foot
Trunk
Head and Neck
Extremity
Time to first metastasis
< 12 months
12-35 months
>36 months
Ploidy
Diploid
Tetraploid
Aneuploid
S-phase
<5%
5-9.9%
>10%
aOne-sided 95% confider
is not calculable.
buffer, pH7.6, as described by Schutte et al. (1985). The
sample was incubated overnight in a 37°C shaking water-
bath. Next day a citrate buffer containing trypsin inhibitor
(T9253, Sigma) and RNAse was added before filtration of
the sample through a 401m nylon mesh. The nuclei suspen-
sion were stained with propidium iodide, 0.13 mg ml-'
(Vindel0v et al., 1983), and kept on ice in darkness until flow
cytometric analysis.
DNA analysis was performed with a FACScan flow
cytometer (Becton Dickinson) equipped with a 15 mWatt
argon laser source (488 nm) to excite the propidium iodide.
Histograms including 20,000 events were recorded. The
percentage of cells in S-phase was estimated assuming a
rectangular distribution (Baisch et al., 1975). The S-phase
was defined as the area between GO/GI and G2/M peaks. All
S-phase values-WEre corrected for background by selecting an
area to the right of the tumour population G2/M with a
representative amount of debris. The mean counts/channel in
this region was subtracted from the mean number of cells in
the S-phase area. The peak with the lowest DNA value was
defined as diploid. Histograms with a single GO/GI peak
were regarded as indicating a diploid tumour, whereas any
additional peak was taken to indicate the presence of an
32
21
37
24
32
30
19
64
21
30
37
10
34
25
24
32
34
21
36
24
19
40
24
21
38
21
34
54
39
25
20
22-37
11-38
22-a
15-33
16-a
21 -45
15-33
11-a
16-32
17-54
33-a
10-a
19-a
17-39
14-38
16-36
20-45
11-24
28-61
14-37
11-32
15-a
17-34
11-34
17-a
15-24
25-61
20-a
28-a
17-37
14-30
P =0.57
P = 0.08
P = 0.13
P = 0.41
P =0.71
P = 0.24
P = 0.07
P =0.56
P = 0.005
P = 0.006
P = 0.012
11 45 33 -a
21 32 20-45
15 19 10-28
nce interval is given when a two-sided confidence interval
aneuploid tumour. Since no built-in correction factor was
used for doublets the criteria for DNA tetraploidy were the
findings of 15% of the cells in the tetraploid region, i.e.
DNA-index of 1.9-2.1 in combination with presence of a
corresponding G2/M peak. In our material the mean
coefficient of variation was 6.1% for diploid, 6.2% for tetra-
ploid, and 7.2% for aneuploid peaks.
Statistics
Cancer survival curves were estimated according to the
method ofKaplan and Meier (1958). We have also calculated
median survival times with 95% confidence intervals
(Brookmeyer & Crowley, 1982). The logrank method was
used to test the significance of the association to survival of
each factor taken separately (Peto et al., 1977). Since all factofg with three categories or more were considered to be
of ordinal type, the trend test version of the logrank method
was used as the prime method by numbering the categories 1, 2, 3 etc. This test was used also for DNA ploidy where the
DNA tetraploid group was expected to have an intermediate
survival. Multivariate survival analysis was performed using the proportional hazards model of Cox (1972). In all survival136 M. KARLSSON
analyses, only cancer deaths were considered as uncensored
observations.
Results
In the total material 36 tumours were DNA diploid, 11 were
tetraploid and 35 were aneuploid. Time to first metastasis
and ploidy was found significantly associated with survival
using univariate analysis (Table I), but there was no correla-
tion between DNA ploidy and time to first metastasis.
Neither was there any correlation between the other variables
mentioned in Table I. The correlations between time to first
metastases and DNA ploidy with survival were such that
long survival was associated with DNA diploid tumour and
late time to first metastasis (Figures 1 and 2). The five year
survival for patients with DNA diploid melanomas was 41%,
for tetraploid 34% and for aneuploid 14%. None of the
other variables in Table I influenced stage III prognosis.
Using multivariate analysis both time to first metastasis and
ploidy remained significant prognostic factors after adjust-
ment for each other (Table II).
A reliable S-phase fraction was found in 47 primary
melanomas. Aneuploid melanomas tended to have a higher
S-phase fraction (mean 9.4%, s.d. 3.8) than diploid ones
(mean 7.1%, s.d. 3.9). There was a significant association
between S-phase fraction and survival (Table I, Figure 3),
and also in multivariate analysis was S-phase fraction
significantly correlated (P = 0.017) to survival, even after
adjustment for ploidy and recurrence-free survival (Table
III).
The median survival time was 32 months in group A
(Linkoping) and 21 months in group B (Gothenburg) with no
statistically significant difference between the groups. The
S-phase was higher (P = 0.034) in group B (mean 9.7%) than
in group A (mean 7.0%). However, adjustments for patients
group did not change the results reported above. In our
study there were similar survival curves for aneuploid
tumours whether treated in Linkoping or in Gothenburg.
This was also the case with diploid tumours (Figure 4).
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Figure 1 Survival curves for stage III patients divided according
to length of disease-free interval, <12 months (n = 44), 12-35
months (n = 22) and > 36 months (n = 16). A long disease-free
interval was correlated to a longer post-recurrence survival
(P = 0.005).
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Figure 2 Relations between survival and ploidy in 82 patients
with stage III melanoma disease. Patients with diploid primary
malignant melanomas (n = 36) had a more favourable prognosis
compared with tetraploid (n = 11) and aneuploid melanomas
(n = 35) when regional metastases occurred (P = 0.006).
Discussion
Ulceration and growth pattern of the primary melanoma
have previously been shown to be important predictive fac-
tors once nodal metastases have occurred, while the thickness
of the melanoma seems to be of less importance (Balch et al.,
1981; Cascinelli et al., 1984).
The prognostic significance of DNA-ploidy and S-phase of
the primary melanoma in stage I (Kheir et al., 1988; Lind-
Table II Cox's regression, analysis of the relationship between post-recurrence
survival and recurrence-free interval, and DNA ploidy in malignant
melanoma
Variable Relative 95% confidence Test of
category n death rate interval significance
Recurrence-free interval P = 0.006a
< 12 months 44 1.0
12-35 months 22 0.6 0.3-1.1
.36 months 16 0.4 0.2-0.9
DNA ploidyb P = 0.01 la
Diploid 36 1.0 -
Tetraploid 11 1.2 0.5-2.7
Aneuploid 35 2.0 1.2-3.6
aTest for trend. bDetermined on the primary tumour.
Table III Cox's regression, analysis of the relationship between
post-recurrence survival and S-phase fraction in stage III malignant
melanoma
Variable Relative 95% confidence Test of
category n death ratec interval significance
S-phase fractionb P=0.017a
<5% 1 1 1.0 -
5-9.9% 21 2.0 0.7- 5.9
.10% 15 4.1 1.2-13.6
aTest for trend. bDetermined on the primary tumour. cAdjusted for DNA
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Figure 3 Survival curves for 47 melanoma patients with stage III
disease, subclassified according to S-phase of primary tumour.
The number of cases were 11 patients with S-phase <5%, 21
with S-phase 5.0-9.9% and 15 with S-phase > 10%. The S-phase
was found to be a significant prognostic variable (P = 0.012).
---- Group A, euploid tumour
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Figure 4 Survival curves for stage III melanoma patients in
relation to DNA ploidy and groups. Group A had adjuvant
chemotherapy and group B had not. The number of cases were:
Group A, euploid (diploid and tetraploid) tumours (n = 34).
Group B, euploid (diploid and tetraploid) tumours (n = 23).
Group A, aneuploid tumours (n= 13) and Group B, aneuploid
tumours (n= 12).
hoim et al., 1990; Wass et al., 1985; Bartkowiak et al., 1991)
and of the melanoma metastases in stage III and IV (Hans-
son et al., 1982; Wass et al., 1985; Muhonen et al., 1991) has
earlier been investigated. However, no study has appeared on
the prognostic influence of the S-phase and the ploidy as
measured on the primary melanoma in patient materials
defined by recurrence (stage III). Wass et a!. (1985) measured
DNA ploidy and S-phase in both primary melanoma and
melanoma metastases, but not in the same patients. Direct
comparison of their results for primary melanoma and
metastases was therefore not possible, but in serial biopsies
of metastases changes in DNA profiles were observed. It is
therefore possible that changes in DNA ploidy can occur
from primary lesion to metastases. The question of what
tumour material is of best value for prognostic evaluation
can not be addressed from our material.
In the present study time to the first metastasis was a
signficant factor correlated to survival. This is similar to the
findings with breast cancer, that a long disease-free interval
was correlated with a significantly reduced mortality risk
(Hatschek et al., 1989). There was also a correlation between
survival time from the first metastasis and the S-phase of the
primary tumour. Patients with S-phase fraction less than 5%
survived longer than those with values above 10%. The
ploidy of the tumour was correlated to survival, i.e. patients
with diploid tumours survived longer than those with aneu-
ploid ones. This is also similar to findings with breast cancer
(Stal et al., 1991) but in contrast to an earlier study which
found that patients with aneuploid melanoma metastases had
improved survival (Muhonen et al., 1991).
In our primary melanomas S-phase was higher in DNA
aneuploid tumours as compared to DNA diploid ones, a
result similar to previous findings (Hansson et al., 1982;
Muhonen et al., 1991), after measurements on melanoma
metastases.
The melanomas in the present study were collected from
two different University Hospitals. In one of them (group A)
the patients were given adjuvant chemotherapy when metas-
tases occurred, but not in group B. Muhonen et al. (1991)
found that patients with aneuploid metastases had improved
survival as compared to patients with diploid metastases,
indicating better chemotherapy responses in aneuploid cases.
This was not corroborated in our study which shows similar
survival curves for aneuploid tumours whether given
adjuvant chemotherapy or not. This was also the case with
diploid tumours (Figure 4).
We can observe that group B had higher S-phase than
group A which may result in a tendency to shorter survival
for this group. The higher S-phase in group B might also be
explained by the fact that the melanomas in group B were
diagnosed between 17 and 25 years ago, so the formalin fixed
and paraffin-embedded tumour material in this group was
older than in group A. Jacobsen et al. (1988) found a strong
correlation between ploidy as measured in fresh and paraffin-
embedded melanomas, while that of the S-phase fraction was
weaker. Adjustments for patients group or year of primary
diagnosis however, did not affect our results.
In summary; the present study shows that patients with a
DNA aneuploid primary melanoma or a high S-phase frac-
tion or an early development of regional recurrence have an
unfavourable post-recurrence prognosis.
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